A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
Olivier Rixe, Sandra X. Franco, Denise A. Yardley, Stephen R. Johnston, Miguel Martin, Banu K. Arun, Stephen P. Letrent, Hope S. Rugo
Dive into the research topics of 'A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer'. Together they form a unique fingerprint.